Trial Profile
A Phase I Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Avacincaptad pegol (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions
- Sponsors IVERIC bio
- 25 Apr 2014 New trial record